Cargando…

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

BACKGROUND: Clinical response to chemotherapy for ovarian cancer is frequently compromised by the development of drug-resistant disease. The underlying molecular mechanisms and implications for prescription of routinely prescribed chemotherapy drugs are poorly understood. METHODS: We created novel A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaidyanathan, Aparajitha, Sawers, Lynne, Gannon, Anne-Louise, Chakravarty, Probir, Scott, Alison L, Bray, Susan E, Ferguson, Michelle J, Smith, Gillian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985349/ https://www.ncbi.nlm.nih.gov/pubmed/27415012 http://dx.doi.org/10.1038/bjc.2016.203

Ejemplares similares

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
por: Schmidt, M, et al.
Publicado: (2007)

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
por: Toner, A P, et al.
Publicado: (2013)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
por: Chen, H, et al.
Publicado: (2009)

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells
por: Stein, U, et al.
Publicado: (2012)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells
por: Lucia, M B, et al.
Publicado: (2011)

Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells
por: Yang, Q, et al.
Publicado: (2014)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

A leukotriene B(4) receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells
por: Kim, H, et al.
Publicado: (2013)

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
por: Hu, X F, et al.
Publicado: (2007)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
por: Hamaguchi, T, et al.
Publicado: (2005)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy
por: Koukourakis, M I, et al.
Publicado: (2014)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer
por: Sun, S, et al.
Publicado: (2015)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
por: Codony-Servat, Jordi, et al.
Publicado: (2017)

High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients
por: Bai, Tuya, et al.
Publicado: (2017)

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Piro, G, et al.
Publicado: (2015)

The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells
por: Pillozzi, Serena, et al.
Publicado: (2018)

Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1
por: de Groot, D J A, et al.
Publicado: (2007)

Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer
por: Tanaka, N, et al.
Publicado: (2011)

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death
por: Obiorah, I, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vc5frfa4v8tn1g0up04o1mcpdk